other material
confidence high
sentiment positive
materiality 0.75
Caribou Biosciences reports CB-010 ANTLER Phase 1 data: 14.4 mo median PFS with partial HLA matching
Caribou Biosciences, Inc.
- Median PFS of 14.4 months with ≥4 HLA matches (N=13) vs 2.8 months with ≤3 matches (N=33).
- In LBCL patients with ≥4 HLA matches (N=11), median PFS not reached; ORR 91%, CR rate 36%.
- No Grade ≥3 CRS or GvHD observed; RP2D selected at 80x10^6 CAR-T cells.
- Plan to enroll ~20 additional 2L LBCL patients prospectively; initial data expected H1 2025.
- Pivotal Phase 3 trial for CB-010 in 2L LBCL planned for H2 2025 if confirmed.